Aligos Therapeutics (ALGS) director granted 5,860 options at $5.50 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aligos Therapeutics director Bridget A. Martell received a grant of 5,860 stock options to buy common shares at an exercise price of $5.50 per share. The options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2027 annual stockholder meeting, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Martell Bridget A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,860	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,860 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 5,860 options Exercise price: $5.50 per share Underlying shares: 5,860 shares +2 more

5 metrics

Options granted 5,860 options Stock Option (Right to Buy) grant to director on June 25, 2026

Exercise price $5.50 per share Conversion or exercise price for the stock options

Underlying shares 5,860 shares Common stock underlying the option grant

Post-grant derivative holdings 5,860 derivative securities Total options held following this transaction

Option expiration June 25, 2036 Expiration date of the granted options

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 5.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares"

annual meeting financial

"immediately prior to the annual meeting in 2027 of the Issuer's stockholders"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

continuous service financial

"subject to continuous service to the Issuer through such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:37 PM Accepted by SEC EDGAR 06/29/2026 - 04:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martell Bridget A

(Last)

(First)

(Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.5	06/25/2026		A		5,860		⁽¹⁾	06/25/2036	Common Stock	5,860	$0	5,860	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

	/s/ Lesley Ann Calhoun, as attorney-in fact for Bridget Martell	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Aligos Therapeutics (ALGS) disclose in this Form 4?

Aligos Therapeutics reported a stock option grant to director Bridget A. Martell. She received options for 5,860 shares of common stock, reflecting routine equity-based director compensation rather than an open-market share purchase or sale.

How many Aligos Therapeutics (ALGS) options did the director receive?

Director Bridget A. Martell received 5,860 stock options. Each option represents the right to buy one share of Aligos Therapeutics common stock, bringing her total reported option holdings from this grant to 5,860 derivative securities following the transaction.

What is the exercise price of the new Aligos Therapeutics (ALGS) options?

The granted options have an exercise price of $5.50 per share. This is the price at which Bridget A. Martell can purchase Aligos Therapeutics common stock once the options have vested and become exercisable under the grant terms.

When do Bridget A. Martell’s Aligos Therapeutics (ALGS) options vest?

The options vest 100% on the earlier of the first anniversary of the grant date or immediately prior to Aligos Therapeutics’ 2027 annual stockholder meeting. Vesting is conditioned on her continuous service to the company through the applicable vesting date.

When do the new Aligos Therapeutics (ALGS) options expire?

The granted stock options expire on June 25, 2036. After this expiration date, Bridget A. Martell would no longer be able to exercise any unexercised options from this grant, even if they had previously vested according to the award’s terms.

Is this Aligos Therapeutics (ALGS) Form 4 an open-market trade?

No, the Form 4 reflects a compensation-related option grant, coded as a grant or award acquisition. It does not report an open-market purchase or sale of Aligos Therapeutics common stock by the director in the public markets.